January 19, 2017 9:20 PM ET

Pharmaceuticals

Company Overview of S-TARget therapeutics GmbH

Company Overview

S-TARget therapeutics GmbH, a biotech company, develops therapeutic vaccines to cure and prevent allergic diseases. Its SG100, an active immunotherapy prototype that is used to cure and prevent allergic asthma induced by house dust mite (HDM). The company’s SG100 vaccine comprises of active ingredients that work together in a two-module system, such as a generic module (warhead) and a disease-specific module (immunogen). S-TARget therapeutics GmbH was founded in 2010 and is based in Vienna, Austria.

Gastgebgasse 5-13

Vienna,  1230

Austria

Founded in 2010

Phone:

43 664 5160032

Key Executives for S-TARget therapeutics GmbH

Founder, Chief Executive Officer and Managing Director
Founder, Managing Director and Chief Scientific Officer
Compensation as of Fiscal Year 2016.

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
 

The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
Bloomberg L.P. United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact S-TARget therapeutics GmbH, please visit www.s-target.com. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.